Whether for drug screening or toxicity testing, stem cell-based 3D tissue models are key to biomedical research. However, producing cell aggregates in bioreactors is highly complex and cost-intensive. Until now, quality has only been checked at the end of the process. This entails a high risk of lost time and material.